Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses

  • ImmunityBio Inc IBRX has reported initial data from the Phase 1 study evaluating its hAd5 COVID-19 vaccine candidate in healthy participants.
  • Just 14-16 days after the single dose of the vaccine, the mean level of T cells generated in response to dual antigen hAd5 spike (S) + nucleocapsid (N) vaccine was ten times higher for N specific T cells.
  • By day 21, both S and N T cell responses achieved levels ten times higher than pre-vaccination levels.
  • Data also indicated that the hAd5 S+N vaccine could provide protection against both the first wave SARS-CoV-2 and variants.
  • The mean T cell levels seen in the vaccinated participants were equivalent to those for patients recovered from infection by the SARS-CoV-2 virus.
  • This second-generation hAd5 vectored vaccine targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins to generate B and T cell memory to these antigens and long-term immunity to the virus.
  • Price Action: IBRX shares are trading 1.55% higher at $19.03 during the market trading session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralCOVID-19 VaccinePhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!